Pfizer Inc. last week completed two acquisitions that are designed to expand its skin care expertise and market reach. On Dec. 2, the firm finished its deal for Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis (skin scarring), and the day prior it closed the deal on its acquisition of Ferrosan Consumer Health’s business. “It is imperative at Pfizer that we continue to develop new and innovat...